Development of a curative treatment within the AML-BFM studies

Klinische Padiatrie

Volumn 225, Issue SUPPL1, 2013, Pages

  Creutzig, U ^a   Zimmermann, M ^a   Dworzak, M N ^b   Ritter, J ^c   Schellong, G ^c   Reinhardt, D ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

acute myeloid leukaemia; AML BFM studies; children; diagnosis; treatment

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; MYELOPEROXIDASE; NONSPECIFIC ESTERASE; RETINOIC ACID; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRAIN LEUKEMIA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHROMOSOME TRANSLOCATION 7; CYTOCHEMISTRY; CYTOGENETICS; DOWN SYNDROME; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EVENT FREE SURVIVAL; GERMANY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; LONG TERM SURVIVAL; LOW DRUG DOSE; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROMYELOCYTIC LEUKEMIA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK ASSESSMENT; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GERMANY; HUMANS; IDARUBICIN; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; METHOTREXATE; MULTICENTER STUDIES AS TOPIC; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; THIOGUANINE; VINCRISTINE;

EID: 84878076239     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0033-1337968     Document Type: Article

References (74)

1. Vereinbarung des Gemeinsamen Bundesausschusses über Maßnahmen zur Qualitätssicherung für die stationäre Versorgung von Kindern und Jugendlichen mit hämato-onkologischen Krankheiten gemäß § 137 Abs. 1 Satz 3 Nr. 2 SGB V für nach § 108 SGB V zugelassene Krankenhäuser (Vereinbarung zur Kinderonkologie). http://www.g-ba.de/ informationen/beschluesse/290/2006
2. Abrahamsson J., Forestier E., Heldrup J. et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol: 2011; 29 310 315
3. Bene M. C., Castoldi G., Knapp W. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia: 1995; 9 1783 1786
4. Bennett J. M., Catovsky D., Daniel M. T. et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med: 1985; 103 626 629
5. Bennett J. M., Catovsky D., Daniel M. T. et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol: 1991; 78 325 329
6. Bielack S. S., Erttmann R., Kempf Bielack B. et al. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer: 1996; 32A 1652 1660 (Pubitemid 26306872)
7. Burnett A. K., Hills R. K., Milligan D. W. et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol: 2010; 28 586 595
8. Corrigan J. J., Feig S. A. Guidelines for pediatric cancer centers. Pediatrics: 2004; 113 1833 1835
9. Creutzig U. Kommentar: Krebs bei Kindern und Jugendlichen - Versorgung in Zentren. Dtsch Arztebl: 2012; 109 A-18/B-15/C-15-
10. Creutzig U., Reinhardt D. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A European view. Br J Haematol: 2002; 118 365 377 (Pubitemid 34994637)
11. Creutzig U., Reinhardt D., Diekamp S. et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia: 2005; 19 1355 1360 (Pubitemid 41136328)
12. Creutzig U., Reinhardt D., Zimmermann M. et al. Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: a matter of controversies. Blood: 2001; 97 3671 3672
13. Creutzig U., Ritter J., Budde M. et al. Aktuelle Ergebnisse der kooperativen AMLTherapiestudien bei Kindern: BFM-78 und -83. Klin Pädiatr: 1986; 198 183 190 (Pubitemid 16098810)
14. Creutzig U., Ritter J., Budde M. et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer: 1987; 60 3071 3079 (Pubitemid 18013184)
15. Creutzig U., Ritter J., Niederbierbaum-Koczy G. et al. Prognostische Bedeutung der Eosinophilie bei Kindern mit akuter myeloischer Leukämie in den Studien AMLBFM- 78 und -83. Klin Pädiatr: 1989; 201 220 226 (Pubitemid 19186312)
16. Creutzig U., Ritter J., Riehm H. et al. The childhood AML-studies BFM-78 and -83: Treatment results and risk factor analysis. Haematol Blood Transf: 1987; 30 71 75
17. Creutzig U., Ritter J., Riehm H. et al. Improved treatment results in childhood acute myelogenous leukemia: A report of the German cooperative study AML-BFM-78. Blood: 1985; 65 298 304 (Pubitemid 15163564)
18. Creutzig U., Ritter J., Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood: 1990; 75 1932 1940 (Pubitemid 20180281)
19. Creutzig U., Ritter J., Zimmermann M. et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. Leukemia: 2001; 15 348 354 (Pubitemid 32243767)
20. Creutzig U., Ritter J., Zimmermann M. et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt- Münster 93. J Clin Oncol: 2001; 19 2705 2713 (Pubitemid 32441376)
21. Creutzig U., Ritter J., Zimmermann M. et al. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia (AML): unexpected results of the childhood AML Study BFM-87. J Clin Oncol: 1993; 11 279 286 (Pubitemid 23046818)
22. Creutzig U., Ch Sperling, Harbott J. et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of Study AML-BFM-87. Blood: 1995; 86 3097 3108
23. Creutzig U., Van den Heuvel-Eibrink M. M., Gibson B. et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel, on behalf of the AML Committee of the International BFM Study Group. Blood: 2012; 120 3187 3205
24. Creutzig U., Zimmermann M., Bourquin J. P. et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer: 2011; 57 986 992
25. Creutzig U., Zimmermann M., Bourquin J. P. et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood: 2011; 118 5409 5415
26. Creutzig U., Zimmermann M., Dworzak M. et al. Randomized introduction of liposomal daunorubicin (L-DNR) in a higher equivalent dose than idarubicin during induction: Improved Results in Study AML-BFM 2004. Blood: 2010; 116 83 83
27. Creutzig U., Zimmermann M., Dworzak M. et al. Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity. Blood: 2010; 116 83 83
28. Creutzig U., Zimmermann M., Dworzak M. et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol: 2010; 149 399 409
29. Creutzig U., Zimmermann M., Hannemann J. et al. Quality management within the competence network of paediatric oncology and haematology. Klin Padiatr: 2003; 215 338 340 (Pubitemid 38064633)
30. Creutzig U., Zimmermann M., Lehrnbecher T. et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol: 2006; 24 4499 4506 (Pubitemid 46646248)
31. Creutzig U., Zimmermann M., Reinhardt D. et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol: 2004; 22 4384 4393 (Pubitemid 41185159)
32. Creutzig U., Zimmermann M., Ritter J. et al. Definition of a standard-risk group in children with AML. Br J Haematol: 1999; 104 630 639 (Pubitemid 29119294)
33. Creutzig U., Zimmermann M., Ritter J. et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia: 2005; 19 2030 2042 (Pubitemid 41741595)
34. Diekamp S., Creutzig U., Reinhardt D. et al. Transitorisch myeloproliferatives Syndrom bei Neugeborenen mit Down Syndrom: Überblick und Analyse von 115 Patienten aus den AML-BFM Studien und der ESPED-Studie. Monatsschrift Kinderheilkunde: 2006; 154 162 168 (Pubitemid 43289576)
35. Dohner H., Estey E. H., Amadori S. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood: 2010; 115 453 474
36. Duffner P. K. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist: 2004; 10 293 310 (Pubitemid 39492075)
37. Ehlers S., Herbst C., Zimmermann M. et al. Granulocyte colony-stimulating factor (GCSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol: 2010; 28 2591 2597
38. Fernandez H. F., Sun Z., Yao X. et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med: 2009; 361 1249 1259
39. Franklin J., Alonzo T., Hurwitz C. A. et al. COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML). Blood: 2008; 112 56 56
40. Gibson B. E., Webb D. K., Howman A. J. et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial. British Journal of Haematology: 2011; 155 366 376
41. Harris N. L., Jaffe E. S., Diebold J. et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol: 1999; 17 3835 3849
42. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol: 2001; 2 429 436 (Pubitemid 33585947)
43. Hitzler J. K., Cheung J., Li Y. et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood: 2003; 101 4301 4304 (Pubitemid 36857793)
44. Huang M. E., Ye Y. C., Chen S. R. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood: 1988; 72 567 572
45. Inaba H., Rubnitz J. E., Coustan-Smith E. et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol: 2011; 29 3293 3300
46. Jabbour E., Kantarjian H., Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma: 2004; 45 2187 2195 (Pubitemid 39504312)
47. Kallage V., Muller J. E., Zimmermann M. et al. Prognosis, treatment completion, and complications in nonresponders in the study AML-BFM87. Klin Padiatr: 1999; 211 250 259
48. Klusmann J. H., Creutzig U., Zimmermann M. et al. Treatment and prognostic impact of transient leukemia in neonates with Down's syndrome. Blood: 2008; 111 2991 2998
49. Klusmann J. H., Reinhardt D., Zimmermann M. et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica: 2012; 97 21 29
50. Lehrnbecher T., Varwig D., Kaiser J. et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AMLBFM 93. Leukemia: 2004; 18 72 77 (Pubitemid 38159441)
51. Lie S. O., Abrahamsson J., Clausen N. et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol: 2003; 122 217 225 (Pubitemid 36859606)
52. Lie S. O., Abrahamsson J., Clausen N. et al. Long-term results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia: 2005; 19 2090 2100 (Pubitemid 41741601)
53. Mann G., Reinhardt D., Ritter J. et al. Treatment with all-trans retinoid acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol: 2001; 80 417 422 (Pubitemid 32725460)
54. Niewerth D., Creutzig U., Bierings M. B. et al. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood: 2010; 116 2205 2214
55. Pession A., Rondelli R., Basso G. et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia: 2005; 19 2043 2053 (Pubitemid 41741596)
56. Pui C. H., Howard S. C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol: 2008; 9 257 268 (Pubitemid 351722945)
57. Reinhardt D., Diekamp S., Fleischhack G. et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie: 2004; 27 269 272 (Pubitemid 39279336)
58. Reinhardt D., von Neuhoff C., Sander A. et al. Genetic Prognostic Factors in Childhood Acute Myeloid Leukemia. Klin Padiatr: 2012; 224 372 376
59. Riehm H., Gadner H., Henze G. et al. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol: 1980; 2 299 306 (Pubitemid 11165783)
60. Rubnitz J. E., Inaba H., Dahl G. et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol: 2010; 11 543 552
61. Sander A., Zimmermann M., Dworzak M. et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia: 2010; 24 1422 1428
62. Sievers E. L., Larson R. A., Stadtmauer E. A. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol: 2001; 19 3244 3254 (Pubitemid 32591442)
63. Smith L. A., Cornelius V. R., Plummer C. J. et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer: 2010; 10 337 351
64. th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol: 1998; 101 130 140 (Pubitemid 28197786)
65. Swerdlow S. H., Campo E., Harris N. L. et al. WHO Classification of Tumors of Haemtopoetic and Lymphoid Tissues. 4th, Lyon, France: 2008
66. Testi A. M., Biondi A., Lo C. F. et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood: 2005; 106 447 453 (Pubitemid 40981236)
67. Tsukimoto I., Tawa A., Horibe K. et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol: 2009; 27 4007 4013
68. van Dalen E. C., van der Pal H. J., Caron H. N. et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev: 2009; CD005008
69. Vardiman J. W., Thiele J., Arber D. A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood: 2009; 114 937 951
70. Wechsler J., Greene M., McDevitt M. A. et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet: 2002; 32 148 152 (Pubitemid 34977210)
71. Weinberg O. K., Seetharam M., Ren L. et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood: 2009; 113 1906 1908
72. Woods W. G., Neudorf S., Gold S. et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood: 2001; 97 56 62 (Pubitemid 32061242)
73. Zwaan C. M., Reinhardt D., Corbacioglu S. et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood: 2003; 101 3868 3871 (Pubitemid 36857859)
74. Zwaan C. M., Reinhardt D., Zimmerman M. et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol: 2010; 148 768 776